Nuvectra Corporation Stock

Equities

NVTRQ

US67075N1081

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Nuvectra Corporation +16.67% -85.26%
Sales 2017 31.84M Sales 2018 48.83M Capitalization 288M
Net income 2017 -44M Net income 2018 -48M EV / Sales 2017 2.58 x
Net cash position 2017 1.49M Net cash position 2018 55.16M EV / Sales 2018 4.76 x
P/E ratio 2017
-1.84 x
P/E ratio 2018
-5.02 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 96.76%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 76 16-02-29
Compliance Officer 49 14-12-31
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Chief Executive Officer 76 16-02-29
Director/Board Member 65 16-02-29
More insiders
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
More about the company